Brought to you by 
Sanofi-Synthélabo closes takeover of Aventis
03 Nov 2005
Executive Summary
After weeks of speculation, Sanofi-Synthélabo has launched--with the support of the French government--a hostile bid to acquire its larger rival Aventis SA for €48.3bn ($60bn)--19% in cash and 81% in stock. Sanofi claims the combined pharmaco--which would be ranked the third-largest worldwide in global sales--would have one of the largest R&D budgets in the industry (at €4bn) and would feature a pipeline of almost 60 late-stage candidates. Its therapeutic focus would include cardiovascular/thrombosis, CNS, oncology, diabetes, and urology.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sanofi-Synthélabo closes takeover of Aventis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice